NEW YORK (GenomeWeb News) – BioFocus and DiscoveRx have signed a co-marketing pact that allows BioFocus to offer screening services using DiscoveRx's assay technologies, BioFocus said today.

Under the agreement, BioFocus, based in Saffron Walden, UK, will offer to its customers DiscoverX's PathHunter beta-arrestin GPCR assays, HitHunter cAMP assays, and associated cell lines.

"The addition of the DiscoveRx GPCR product portfolio to BioFocus will enhance our assay development and screening platform,” Chris Newton, senior vice president at BioFocus, said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.

South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.

In Science this week: the synthetic genetic system hachimoji, and more.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.